Introduction
5-Fluorouracil (5-FU) has been widely used for the treatment of gastrointestinal (GI) cancers. Because the effect of 5-FU is time-dependent, administration by continuous intravenous infusion is thought to be more active than that by bolus infusion [1] . However, continuous infusion of 5-FU demands hospital stay and sometimes causes severe side effects, which may limit longterm therapy and the maintenance of quality of life.
S-1 is designed both to enhance the cytotoxic effect of tegafur and to reduce gastrointestinal toxicities. Phase II studies of S-1 for advanced gastric cancer demonstrated a favorable outcome, with response rates of 44% to 49% [2, 3] . The frequency of adverse reactions was over 70%, but that of grade 3 to 4 GI toxicities was less than 2%. In Japan, S-1 has become a first-line regimen for advanced and recurrent gastric cancer (ARGC) because of its efficacy and feasibility for outpatient use; however, its longterm treatment results have not been reported.
In this study, we examined the longterm value of S-1 in the treatment of ARGC.
Patients and methods

Patients
Between June 1999 and June 2001, 69 patients with ARGC were treated with S-1 at Kanagawa Cancer Center. Eligibility criteria were as follows: (1) histologically or cytologically confirmed gastric cancer; (2) adequate bone marrow, renal, and hepatic function; (3) Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2; (4) previous chemotherapy discontinued more than 2 weeks prior to initiation of S-1 treatment; and (5) no known allergy to 5-FU. The median followup time for the patients was 336 days (range, 44 to 1107 days).
Abstract
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The responses to treatment of primary lesions and metastatic lesions were evaluated according to the Japanese Classification of Gastric Cancer (13th edition) [4] and the Response Evaluation Criteria in Solid Tumors (RECIST) [5] . Safety of the treatment was assessed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC, version 2.0).
Statistics
All data were analyzed by SPSS 11.0 J software (SPSS, Chicago, IL, USA). Survival time was calculated, from the initial date of the administration of S-1 to the date of death or the last follow-up date, by the Kaplan-Meier method. (Table 1) Most patients had a pretreatment ECOG performance status of 0 to 1. Forty-four (64%) patients received S-1 as first-line therapy, and 25 (36%) had had prior chemotherapy. As for metastatic sites, peritoneum (43%) and lymph nodes (30%) were the major sites in a total of 76 metastatic lesions in the 69 patients. Response was evaluated in 58 (84%) patients with measurable lesions.
Results
Patients' characteristics
Response and survival
The overall response rate was 38% (complete response [CR], 2/58; partial response [PR], 20/58; stable disease
[SD], 9/58; progressive disease [PD], 23/58). Response rate by target organ was 40% for the primary lesion, 45% for lymph node metastasis, 38% for peritoneal metastasis, and 25% for liver metastasis. Response rate by disease status was 36% for unresectable disease, 44% for recurrent disease, and 25% for remnant disease. When S-1 was administered as second-line chemotherapy, the response rate, at 36%, was almost equal to that of first-line therapy at 39% ( Table 2) .
The median survival time (MST) after the initiation of S-1 administration in all 69 patients was 336 days (95% confidence interval, 215-457 days) with 1-year and 2-year survival rates of 48% and 27%, respectively (Fig. 1) . (Table 3) Adverse reactions appeared in 44 patients (64%). Grade 3 toxicities occurred in 8 patients (12%) and no grade 4 toxicities were observed. The major incidence of adverse reactions was 30% for leucopenia, 29% for anorexia, 19% for neutropenia and skin reaction, 13% for diarrhea, and 12% for anemia. Only 6 patients discontinued S-1 within two courses of treatment due to grade 2 to 3 adverse reactions.
Longterm control
Of the 69 patients, 14 (20%) continued to receive S-1 for more than a year. These 14 patients, 6 men and 8 women, had a median age of 59 years (range, 45 to 72 years). S-1 was administered as first-line therapy in 10 patients, and as second-line therapy in 4. The major target organs were lymph node and peritoneum, in 6 patients each. Six patients responded (CR, 2; PR, 4) and 3 patients maintained SD in lymph node (n ϭ 2) and in the peritoneum (n ϭ 1) during the courses. The MST of these 14 patients after the initiation of S-1 was 918 days (range, 536 to 1107 days). The MSTs for patients with CR, PR, and SD, were 932 days, 698 days, and 800 days, respectively. Toxicities of grade 1 to 2 occurred in 9 patients (64%), while no grade 3 to 4 adverse reactions were observed in this group with longterm control.
Discussion
Chemotherapy provides a significant advantage over best supportive care in patients with advanced and recurrent gastric cancer (ARGC) [6] ; however, a standard regimen against gastric cancer is not yet established.
Combinations of conventional agents, such as FAMTX (5-FU, doxorubicin, methotrexate) [6] [7] [8] , FAM (5-FU, doxorubicin, mitomycin C) [6, 7, 9] , and FP (5-FU, cisplatin) [6, 10] , have demonstrated relatively high response rates in the treatment of advanced gastric cancer. However, none of these regimens has contributed to a prolonged median survival of over 10 months. One reason for this discrepancy between the high response rate and short survival is presumed to be due to side effects, such as myelosuppression and GI toxicity. Especially, GI toxicity, which is caused by the phosphorylation of 5-FU, is not only a dose-limiting factor of 5-FU but may also limit continuous therapy. S-1 is a combination with potassium oxonate (OXO) to inhibit the phosphorylation of 5-FU, and is expected to reduce GI toxicity [11] . In fact, grade 3 to 4 GI toxicity was observed in fewer than 2% of patients in phase II studies of S-1 [2, 3] . These findings suggest that S-1 is suitable for the longterm therapy of patients with gastric cancer.
Another reason for the discrepancy is that peritoneal metastasis is the predominant metastatic pattern in advanced gastric cancer [12] [13] [14] . Patients with peritoneal metastasis usually have no measurable lesions, because the disseminated small nodules cannot be detected by computed tomography (CT). Laparoscopy has been reported to be useful to identify small peritoneal implants and to evaluate the response to chemotherapy for peritoneal metastasis of gastric cancer [15, 16] ; however, routine and repeated use of the procedure is impossible. If the responses to chemotherapy for peritoneal disease were assessed more accurately, the response rate would be lower, because the response of peritoneal metastasis to conventional chemotherapy differs from the response of other metastatic sites.
In our study, S-1 was effective for peritoneal lesions. There were six patients with peritoneal metastasis who survived for more than a year. All of these patients received S-1 for a long period without severe toxicity. Among them, we experienced two patients with metastatic peritoneal disease who received S-1 for more than 2 years. In one of these patients, peritoneal metastasis was diagnosed by the presence of multiple stenoses of the colon and elevated levels of serum tumor markers [17] . After three courses of S-1, barium enema revealed alleviation of the colonic stenosis. Laparoscopy after 11 courses showed negative peritoneal dissemination, while in the other patient, no clinical symptom to suggest disease progression was observed during the courses. At the laparoscopy performed for response evaluation, the peritoneal metastasis was almost the same as that at 2 years before. In fact, three patients have maintained stable disease for a median of 800 days, which is comparable with the MST of the patients who responded (MST, 688 days). These findings suggest that the control of peritoneal disease significantly affects survival, and that S-1 may contribute to this control. Generally, the prognosis of patients with recurrent gastric cancer is poor. In another study, we surveyed 202 patients with recurrent gastric cancer [18] . In these patients, the MST for 149 patients who were treated with anticancer agents other than S-1 was 211 days, which was significantly shorter than that of the patients treated with S-1, and it was especially shorter than that of the patients treated by S-1 for over a year (MST, 918 days). This result suggests that longterm administration of S-1 may also contribute to the survival period of patients with ARGC.
In summary, longterm administration of S-1 is feasible and useful for disease control of ARGC because of its low GI toxicity and efficacy in peritoneal metastasis, resulting in long survival.
Conclusion
Longterm administration of S-1 may benefit patients with ARGC, irrespective of the target organ, providing prolonged disease control with acceptable toxicities.
